Clinical-stage biopharmaceutical company developing therapeutics and high-end modified formulations for unmet needs in oncology, immunology, infectious diseases, and dermatology
Clinical-stage biopharmaceutical company developing therapeutics and high-end modified formulations for unmet needs in oncology, immunology, infectious diseases, and dermatology. Its proprietary SprāSol® formulation platform is designed to improve the solubility and bioavailability of poorly soluble small molecules and PROTACs. The pipeline includes Phase 1 and Phase 2 programs.